Wesbanco Bank Inc. Takes $244,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Wesbanco Bank Inc. bought a new position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 55,000 shares of the company's stock, valued at approximately $244,000. Wesbanco Bank Inc. owned about 0.12% of Y-mAbs Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS acquired a new position in shares of Y-mAbs Therapeutics in the fourth quarter worth approximately $46,000. ProShare Advisors LLC acquired a new position in shares of Y-mAbs Therapeutics in the 4th quarter worth approximately $99,000. Wells Fargo & Company MN boosted its stake in shares of Y-mAbs Therapeutics by 54.1% in the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock valued at $137,000 after purchasing an additional 6,131 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock valued at $139,000 after purchasing an additional 4,163 shares during the last quarter. Finally, XTX Topco Ltd increased its position in shares of Y-mAbs Therapeutics by 83.8% during the fourth quarter. XTX Topco Ltd now owns 20,768 shares of the company's stock worth $163,000 after buying an additional 9,468 shares during the period. 70.85% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently issued reports on YMAB. Truist Financial dropped their target price on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. HC Wainwright cut their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Oppenheimer decreased their target price on Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday, May 29th. Morgan Stanley lowered their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a report on Wednesday, March 5th. Finally, Wedbush restated an "outperform" rating and set a $18.00 price target (down from $21.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, May 28th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.60.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ YMAB traded up $0.08 during mid-day trading on Friday, reaching $4.71. 472,812 shares of the company's stock traded hands, compared to its average volume of 304,554. The business has a 50-day simple moving average of $4.44 and a 200 day simple moving average of $5.92. The stock has a market cap of $213.29 million, a P/E ratio of -8.72 and a beta of 0.52. Y-mAbs Therapeutics, Inc. has a 1-year low of $3.55 and a 1-year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.10. The firm had revenue of $20.90 million during the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. Equities research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.